Target intelligence / Profile preview

DNA polymerase alpha catalytic subunit (POLA1) (POLA1)

Target
POLA1
Molecular classification
Enzyme, DNA-directed DNA polymerase, Transferase, Nucleotidyltransferase
01

Overview

DNA polymerase alpha catalytic subunit (POLA1) is a fundamental enzyme responsible for the initiation of DNA replication in eukaryotic cells. As the largest subunit of the four-protein DNA polymerase alpha-primase complex, it extends the short RNA primers synthesized by the primase subunits with approximately 20 deoxynucleotides, creating the RNA-DNA chimeric primers required for the processive polymerases delta and epsilon to take over. Beyond its nuclear role in the S phase of the cell cycle, POLA1 also functions in the cytosol to maintain a physiological concentration of RNA:DNA hybrids, which serve as critical negative regulators of the cGAS-STING pathway to prevent the spontaneous activation of type I interferon responses. Mutations in the POLA1 gene are associated with rare X-linked disorders such as reticulate pigmentary disorder (XLPDR) and Van Esch-O'Driscoll syndrome (VEODS), which manifest as immunodeficiency, growth retardation, and autoinflammation. In the context of oncology, POLA1 is frequently overexpressed in various malignancies, including colorectal and bladder cancers, making it a viable therapeutic target for small-molecule inhibitors like CD437 and ST1926 that induce replication stress and apoptosis in rapidly proliferating cells.

Other names
DNA polymerase alpha 1p180POLANSXPDRVEODSPolymerase (DNA directed), alpha 1
02

Mechanism of action

Inhibition of the catalytic active site to prevent DNA template and nucleotide binding, leading to the disruption of RNA-DNA primer synthesis, induction of replication stress, and triggering of apoptosis.

03

Biological functions

DNA replication initiationRNA-DNA primer synthesisOkazaki fragment synthesisRegulation of type I interferon activationGenome stabilityCell cycle regulationTelomere maintenance
04

Disease associations

CancerX-linked reticulate pigmentary disorder (XLPDR)Van Esch-O'Driscoll syndrome (VEODS)ImmunodeficiencyIntellectual disabilityInflammation
05

Safety considerations

Potential embryonic lethality (essential gene)Systemic toxicity due to inhibition of normal cell divisionHyperactivation of type I interferon response leading to sterile inflammationGenomic instability and replication stress
06

Interacting drugs

CD437

5 more in the full profile.

07

Biomarkers

POLA1 mRNA/protein expression levelsCytosolic RNA:DNA hybrid levelsType I interferon (IFN-alpha/beta) levelsNatural Killer (NK) cell count and function

Beyond the preview

Go deeper on DNA polymerase alpha catalytic subunit (POLA1) (POLA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA polymerase alpha catalytic subunit (POLA1) (POLA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call